A UNC Chapel Hill analysis of NHANES data found that only 12.2% of American adults (about 27.3 million people) are metabolically healthy. Among adults with obesity, fewer than 1% met that bar.
Most searches for a “metabolic health test” return the same five metabolic syndrome markers: waist circumference, triglycerides, HDL, blood pressure, and fasting glucose. These results rarely explain the physiology behind each one or how they relate to each other over time.
This article sequences biomarkers by how early each one detects dysfunction, starting with insulin-level markers (fasting insulin, HOMA-IR, TyG), then moving to glucose-level markers (A1C, fasting glucose), lipid-particle markers (ApoB vs. LDL-C), and finally inflammation (hs-CRP).
The Problem with the Standard Five-Marker Checklist
Under the NCEP ATP III definition, any 3 of 5 factors confirm metabolic syndrome:
- Elevated waist circumference
- Triglycerides of 150 mg/dL or higher
- Low HDL cholesterol
- Elevated blood pressure
- Elevated fasting glucose
According to Quest Diagnostics, metabolic syndrome affects almost half of U.S. adults and is considered a sign of insulin resistance. By the time someone meets three criteria, dysfunction has often been present for years. These five markers describe the syndrome’s visible consequences, not its earliest cause, which is why this article starts further upstream.
Fasting Insulin and HOMA-IR: The Earliest Warning Sign
Fasting insulin and HOMA-IR can flag insulin resistance years before fasting glucose or A1C move out of range. The pancreas compensates with higher insulin output long before glucose control fails.
What Fasting Insulin Actually Measures
Insulin signals cells to take up glucose from the bloodstream. When fasting insulin rises, cells have become resistant to that signal. A “normal” fasting glucose can mask high circulating insulin. In that situation, the body is working harder to achieve the same result, and standard panels do not show it.
How HOMA-IR Is Calculated and What the Score Ranges Mean
HOMA-IR = (fasting insulin × fasting glucose) / 405 in US units, or divided by 22.5 in SI units.
| HOMA-IR Score | Interpretation |
|---|---|
| Below 1.0 | Excellent insulin sensitivity |
| 1.0 to 1.9 | Normal |
| 2.0 to 2.9 | Early-to-moderate resistance |
| 3.0 and above | Clinically significant resistance |
HOMA-IR is a calculated index from two inexpensive blood draws. It is not a specialized or costly test.
Why Insulin Rises Before Glucose Does
As cells resist insulin’s signal, the pancreas secretes more insulin to keep glucose normal. This compensation can continue for years before it begins to fail. For this reason, fasting glucose and A1C are considered lagging markers rather than early ones.
The TyG Index: A Low-Cost, Research-Grade Alternative
The TyG index is an insulin-resistance surrogate that requires no insulin assay. It is built from two values already on routine panels.
What the TyG Index Measures and How It’s Calculated
TyG = ln[fasting triglycerides (mg/dL) × fasting glucose (mg/dL) / 2]
The logic is physiological. Insulin normally suppresses fat release from the liver and fat tissue. When that suppression fails, triglycerides rise alongside glucose.
TyG vs. HOMA-IR: Why Some Research Favors TyG
Cohort research supports TyG as a reliable surrogate for insulin resistance, including the PURE study published in The Lancet Healthy Longevity. Several studies have found that TyG outperformed HOMA-IR in predicting incident type 2 diabetes and cardiovascular events.
One reason is consistency. TyG does not depend on insulin assays, which vary between labs, so it is more reproducible and accessible.
The tradeoff is that TyG is a surrogate, not a direct insulin measurement. It is best read alongside insulin-based markers, not instead of them.
A1C and Fasting Glucose: Where Most Standard Panels Start
These are the markers most people associate with metabolic testing. They also mark the point where hidden dysfunction becomes visible on a basic panel.
What A1C Actually Reflects
A1C measures the percentage of hemoglobin that has glucose bound to it. Because red blood cells live for roughly 2 to 3 months, A1C reflects average blood sugar over that period. As a rolling average, it can catch sustained elevation that a single fasting draw might miss on a good day.
What Fasting Glucose Measures (and Its Blind Spots)
Fasting glucose is a single point-in-time reading taken after an overnight fast. Insulin compensation can hold this number in range long after resistance begins, which is why fasting glucose is typically one of the later markers to move.
Diagnostic Ranges and Why Prediabetes Is Underdiagnosed
The CDC and ADA use these A1C ranges:
- Normal: below 5.7%
- Prediabetes: 5.7% to 6.4%
- Diabetes: 6.5% or above
An estimated 97.6 million U.S. adults (38%) have prediabetes, and roughly 80% of them are unaware of it. This gap is a strong argument for testing further upstream.
Lipid Markers: ApoB vs. LDL-C and the Discordance Problem
Once glucose regulation shifts, lipid particle abnormalities often follow. Counting particles gives a more accurate picture than measuring cholesterol content alone.
What LDL-C Actually Measures
LDL-C estimates the cholesterol carried inside LDL particles. It is not a count of the particles themselves. Two people can have identical LDL-C but very different numbers of atherogenic particles, especially when triglycerides are elevated.
What ApoB Measures Differently
Each atherogenic particle (LDL, VLDL, IDL, Lp(a)) carries exactly one ApoB protein. ApoB is therefore a direct particle count rather than an estimate of cargo.
Systematic reviews and discordance analyses show that ApoB predicts cardiovascular risk more accurately than LDL-C or non-HDL-C. This advantage is most pronounced in people with insulin resistance, diabetes, or high triglycerides.
The Discordance Problem: When LDL-C and ApoB Disagree
Roughly 1 in 5 adults shows discordance between LDL-C and ApoB. When the two values disagree, risk tracks with ApoB. Someone with “normal” LDL-C may still carry elevated particle-level risk.
This discordance is especially common in people with insulin resistance or elevated triglycerides, which links it directly to the earlier markers.
hs-CRP: Measuring the Inflammation Behind Metabolic Dysfunction
Inflammation often accompanies the insulin resistance and lipid abnormalities described above, and it can be driven by them.
What hs-CRP Detects
A standard CRP test is designed to detect acute infection or injury. High-sensitivity CRP detects low-grade systemic inflammation at concentrations too subtle for that standard test. Visceral fat is metabolically active and can release inflammatory signals, which links fat distribution to measurable inflammation.
Reading hs-CRP Risk Categories
- Below 1.0 mg/L: low risk
- 1.0 to 3.0 mg/L: moderate risk
- Above 3.0 mg/L: higher cardiovascular and metabolic risk
hs-CRP is nonspecific, so it is interpreted in context with other markers rather than on its own.
Supporting Markers Worth Knowing: Uric Acid and ALT
Serum uric acid is associated with insulin resistance, hepatic fat accumulation, and metabolic syndrome. It is often an early signal of liver involvement.
ALT is a liver enzyme that correlates with components of metabolic syndrome. Clinicians use it as a marker of fatty liver disease.
Both are corroborating markers rather than first-line screening tools. They are most useful once the primary markers show abnormality.
Putting the Sequence Together: How Markers Typically Go Abnormal in Order
Metabolic dysfunction tends to appear in a typical order:
- Insulin resistance develops first. It is detectable through fasting insulin, HOMA-IR, and TyG.
- Compensation eventually fails. Fasting glucose and A1C move out of range.
- Lipid particle abnormalities develop. ApoB and LDL-C discordance often appears alongside or shortly after the glucose changes.
- Chronic inflammation follows. Elevated hs-CRP frequently accompanies more advanced stages.
A single-marker snapshot, such as a glucose check or a lipid panel alone, can miss dysfunction that is already well underway at the insulin level. Research published in Scientific Reports reflects the same concern: researchers are seeking biomarkers that predict cardiovascular events independent of BMI, because weight alone is a poor proxy for metabolic health.
Why a One-Time At-Home Panel Can’t Replace Clinical Interpretation
Ordering biomarkers is only half the equation. The harder and more valuable half is interpreting them against each other and against a specific person’s history.
The Limits of DTC Panels and CGMs for Non-Diabetics
Direct-to-consumer panels vary widely in breadth. Some commercial lab-testing panels cover around 83 biomarkers, while other providers market 100 to 160+ biomarkers across two annual draws. Breadth alone does not guarantee interpretation.
A 2026 Johns Hopkins Public Health review found little clinical evidence that over-the-counter continuous glucose monitors benefit non-diabetics. Existing interpretation guidance was built for people who already have diabetes. A number without context can create false confidence or unnecessary anxiety.
What In-Person Clinical Context Adds
A one-time result misses several things:
- Trends over time
- Correlation across markers, such as whether an elevated TyG lines up with ApoB discordance
- A person’s hormonal, nutritional, and lifestyle context
A single test is a data point, not a diagnosis.
How Red Mountain Approaches Metabolic Biomarker Testing
Red Mountain’s workup is in-person, clinically-led care informed by more than 30 years of real-world patient outcomes and clinical data. Testing sits within the Foundation stage of care: metabolic assessment and initial labs that address a common question, “Why isn’t what I’m doing working anymore?”
A clinician connects insulin, glucose, lipid, and inflammatory markers rather than handing back a list of numbers. Lab data becomes the starting point for an ongoing relationship, informing nutrition strategy, hormone evaluation, and long-term monitoring aimed at metabolism, energy, and longevity.
Conclusion: Reading Your Numbers in the Right Order
Metabolic dysfunction typically appears in order: insulin resistance, then glucose, then lipid particles, then inflammation. Knowing that order changes how any single result should be read. No single biomarker tells the whole story. The value of a metabolic health test lies in the relationships between markers, and clinical judgment turns a printout into an actionable picture.
Next Step: Discuss Your Numbers With a Clinician Who Reads Them in Context
This kind of multi-marker interpretation is what Red Mountain explains in consults. Some readers may recognize themselves in the early-warning markers (fasting insulin, HOMA-IR, or TyG) even with normal glucose or A1C. For them, a consult is usually the next step toward clarity.
